Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation

International Journal of Artificial Organs

Volumn 20, Issue 1, 1997, Pages 18-21

  Lal, S M ^a,b   Gupta, N ^a   Georgiev, O ^a   Ross, G ^a  

^a University of Missouri   (United States)

^b Health Science Center   (United States)

Author keywords

fluvastatin; hypercholesterolemia; hyperlipidemia; renal transplantation

Indexed keywords

CHOLESTEROL; LIPOPROTEINS;

CARDIOVASCULAR DISEASE; CLINICAL OBSERVATION; FLUVASTATIN; HMG-COA REDUCTASE INHIBITOR; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID-LOWERING EFFECTS; RENAL TRANSPLANTATION; RENAL TRANSPLANTS; TOTAL CHOLESTEROLS;

DISEASES;

CHOLESTEROL; FLUINDOSTATIN; LIPID;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MALE;

EID: 0031056067     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889702000105     Document Type: Article

References (25)

1. Bittar AE, Ratcliffe PJ, Richardson AJ, et al. The prevalence of hyperlipidemia in renal transplant recipients. Transplantation 1990; 50: 987-92.
2. Casaretto A, Marchioro TL, Goldsmith R, Bagdade JD. Hyperlipidemia after successful transplantation. Lancet 1974; 1: 481-4.
3. US Renal Data System: Causes of death. Am J Kidney Dis 1994; 24: 88-95.
4. Editorial: Hyperlipidemia after renal transplantation. Lancet 1988; 1: 919-20.
5. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II) JAMA 1993; 269: 3015-23.
6. LaRossa JC, Hunninghake D, Bush D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 1990; 81: 1721-33.
7. Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results: Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351-64.
8. Canner PL, Berge KG, Wenger NK, et al. For the coronary drug project research group. Fifteen-year mortality in coronary drug project patients: long term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
9. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. Am J Cardiology 1995: 76: 485-91.
10. Blankenhorn DM, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashen-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
11. The lovastatin study group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 1988; 260: 359-66.
12. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 1991; 151: 43-9.
13. Moore RA, Callahan MF, Cody M, et al. The effects of the American Heart Association step I diet on hyperlipidemia following renal transplantation. Transplantation 1990; 49: 60-2.
14. Kasiske B, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990; 49: 95-100.
15. Yoshimura N, Oka T, Okamoto M, Oshmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94-9.
16. Martinez-Hernandez B, Persaud JW, Varghese Z, Moorhead JF. Low dose simvastatin is safe in hyperlipidemic transplant patients treated with cyclosporine. Nephrol Dial Trap 1993; 8: 637-41.
17. Lal SM, Petroski GF, Hewett JE, Van Stone JC, Ross Jr G. Effects of nicotinic acid and lovastatin in renal transplant patients. A prospective, randomized, open labelled Crossover Trial. Am J Kidney Dis 1995; 25: 616-22.
18. Lal SM, Trivedi HS, Van Stone JC, Ross Jr G. Lipid lowering effects of AHA Step I and II diets in renal transplant patients. A prospective study, Int J Artif Organs 1994; 17: 423-7.
19. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994; 343: 1554-5.
20. Jacotot B, Banga JD, Pfister P, Mehra M. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group. Br J Clin Pharmacol 1994; 38: 257-63.
21. Banga JD, Jacotot B, Pfister P, Mehra M. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group. Am J Med 1994; 96: 87-93.
22. Peters TK, Muratti EN, Mehra M. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database. Am J Med 1994; 96: 79-83.
23. Davidson MH. Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety. Am J Med 1994; 96: 41-4.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
25. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-83.